ClinicalTrials.gg
RecruitingNCT06644794COMPROSETUpdated Apr 29, 2026

Progesterone-modified Natural Cycle for FET

A Phase 3 interventional study of Progesterone-modified natural cycle preparation for frozen embryo transfer and Hormone replacement therapy cycle preparation for frozen embryo transfer in Infertility, Female, sponsored by Shandong University of Traditional Chinese Medicine. Recruiting at 1 site in China. Open to female participants aged 21 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Shandong University of Traditional Chinese Medicine · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
21 Years to 44 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Infertility, Female with a site in China — 17 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.

Planned enrollment
18th of 51
336 · median 178
Started
2025
with 6 others
Phase 3
6 of 58
1 open now
Primary completion
2027-09
later than 17 of 19 live
Registered
47th of 58
by date
Lead sponsor
3 of 58
Shandong University of Traditional Chinese Medicine

Among the 58 studies in Infertility, Female with a site in China, this one is the 18th largest by planned enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 17 of the 19 other live ones, and was the 47th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

17 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 21 Years to 44 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Infertility, Female with a site in China, or all of them as a file.
02

Study summary

Hormone replacement therapy (HRT) cycles, despite the ease of synchronizing embryo thawing and embryo transfer timing, increase the risk of pregnancies and obstetric complications compared to natural cycles (NC). By ensuring the presence of the corpus luteum while reducing the number of monitoring sessions, the progesterone modified natural cycle (P4mNC) offers more convenience for the patient than the normal NC. This study is designed to compare the effects of P4mNC and HRT cycles on FET outcomes.

03

Conditions studied

  • Infertility, Female

Browse trials for

Keywords

  • Progesterone-modified natural cycle
  • Hormone replacement therapy
  • Frozen-thawed embryo transfer
04

Who can participate

Ages eligible
21 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 21 to 44 years undergoing FBT
  • (BMI) 18-35 kg/m2
  • Having regular ovulatory cycles

Exclusion criteria

Exclusion Criteria:

  • Untreated uterine adhesions
  • Medical to estrogen and progesterone therapy
  • Illnesses contraindicating assisted reproductive technology or pregnancy
  • History of recurrent implantation failures (> 2 embryo transfer failures)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
336 participants (estimated)

Study arms

  • Experimental
    P4mNC group

    On days 8-12 of the menstrual cycle (MC), depending on the length of the patient's MC, transvaginal ultrasound is used to monitor follicular development and endometrial growth. Vaginal micronized progesterone (Utrogestan, Besins, Belgium) is started at 200 mg in the afternoon and 200 mg in the evening when the dominant follicle reached ≥16 mm and the endometrial thickness is at least 7 mm. A blastocyst is transferred on day 5 after the addition of progesterone. On day 14 after blastocyst transfer, serum β-hCG levels are measured. Upon positive serum pregnancy testing, progesterone support will continue until 8-10 weeks of gestation. However, afternoon progesterone use is eliminated for 30 days after embryo transfer.

    Drug: Progesterone-modified natural cycle preparation for frozen embryo transfer

  • Active comparator
    HRT group

    Endometrial preparation will begin on the second day of the menstrual cycle with oral estradiol (E2) valerate at a dose of 2 mg twice daily. When the patient's endometrial thickness is ≥7 mm, vaginal progesterone administration will be initiated at a dose of 200 mg 3 times daily. On day 5 of the progesterone administration, blastocysts are thawed and transferred. For patients with endometrial thickness \<7 mm, patients continued oral E2 until the endometrium is ≥7 mm. On day 14 after blastocyst transfer, serum β-hCG levels are measured. Upon positive serum pregnancy testing, E2 and progesterone supplementation is continued for 8-10 weeks of gestation.

    Drug: Hormone replacement therapy cycle preparation for frozen embryo transfer

Interventions

  • DrugProgesterone-modified natural cycle preparation for frozen embryo transfer

    A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.

  • DrugHormone replacement therapy cycle preparation for frozen embryo transfer

    A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.

06

What researchers measure

Primary outcomes

  1. Live birth

    A live birth is defined as the delivery of any surviving newborn at 28 weeks or more of gestation.

    Time frame: Within 1 year after randomization

Secondary outcomes

  1. Biochemical pregnancy

    Serum level of ß-hCG \> 50 mIU/mL

    Time frame: Two weeks after embryo transfer

  2. Clinical pregnancy

    Fetal heartbeat observed by vaginal ultrasound

    Time frame: Five weeks after embryo transfer

  3. Ongoing pregnancy

    The presence of a gestational sac and fetal heartbeat after 12 weeks of gestation

    Time frame: Ten weeks after embryo transfer

  4. Miscarriage

    A condition in which the embryo or fetus does not survive and is not spontaneously absorbed or expelled from the uterus

    Time frame: Within 28 weeks of pregnancy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Inhorn MC, Patrizio P. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. Hum Reprod Update. 2015 Jul-Aug;21(4):411-26. doi: 10.1093/humupd/dmv016. Epub 2015 Mar 22. PubMed 25801630 ↗
  • Mascarenhas MN, Cheung H, Mathers CD, Stevens GA. Measuring infertility in populations: constructing a standard definition for use with demographic and reproductive health surveys. Popul Health Metr. 2012 Aug 31;10(1):17. doi: 10.1186/1478-7954-10-17. PubMed 22938182 ↗
  • Doody KJ. Cryopreservation and delayed embryo transfer-assisted reproductive technology registry and reporting implications. Fertil Steril. 2014 Jul;102(1):27-31. doi: 10.1016/j.fertnstert.2014.04.048. Epub 2014 Jun 4. PubMed 24907917 ↗
  • Zhang Y, Fu X, Gao S, Gao S, Gao S, Ma J, Chen ZJ. Preparation of the endometrium for frozen embryo transfer: an update on clinical practices. Reprod Biol Endocrinol. 2023 Jun 8;21(1):52. doi: 10.1186/s12958-023-01106-5. PubMed 37291605 ↗
  • Roelens C, Blockeel C. Impact of different endometrial preparation protocols before frozen embryo transfer on pregnancy outcomes: a review. Fertil Steril. 2022 Nov;118(5):820-827. doi: 10.1016/j.fertnstert.2022.09.003. PubMed 36273850 ↗
  • Gu F, Wu Y, Tan M, Hu R, Chen Y, Li X, Lin B, Duan Y, Zhou C, Li P, Ma W, Xu Y. Programmed frozen embryo transfer cycle increased risk of hypertensive disorders of pregnancy: a multicenter cohort study in ovulatory women. Am J Obstet Gynecol MFM. 2023 Jan;5(1):100752. doi: 10.1016/j.ajogmf.2022.100752. Epub 2022 Sep 15. PubMed 36115572 ↗
  • von Versen-Hoynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, Stan Williams R, Rhoton-Vlasak A, Nichols WW, Fleischmann RR, Zhang W, Winn VD, Segal MS, Conrad KP, Baker VL. Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum. Hypertension. 2019 Mar;73(3):640-649. doi: 10.1161/HYPERTENSIONAHA.118.12043. PubMed 30636552 ↗
  • Kornilov N, Polyakov A, Mungalova A, Yakovleva L, Yakovlev P. Progesterone-modified natural cycle preparation for frozen embryo transfer. Reprod Biomed Online. 2024 Nov;49(5):104350. doi: 10.1016/j.rbmo.2024.104350. Epub 2024 Jul 2. PubMed 39244908 ↗
  • Yuan HN, Song JY, Sun ZG. Comparison of progesterone-modified natural cycle and hormone replacement therapy cycle for endometrial preparation in single frozen blastocyst transfer (COMPROSET): protocol for an open-label randomized controlled trial. Front Med (Lausanne). 2025 Apr 28;12:1522004. doi: 10.3389/fmed.2025.1522004. eCollection 2025. PubMed 40357273 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Sep 2027, 30 months after the start.

Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2024
First posted
Oct 16, 2024
StartActual
Mar 5, 2025
Primary completionEst.
Sep 10, 2027
CompletionEst.
Dec 1, 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06644794
Lead sponsor
Shandong University of Traditional Chinese Medicine
Responsible party
Jing-Yan Song (Prof., Shandong University of Traditional Chinese Medicine) — Principal investigator
First posted
Oct 16, 2024
Start date
Mar 5, 2025
Primary completion
Sep 10, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Xian-Ling Cao, MD
Contact
caoxianlingling@163.com
0531-68901236
Zhen-Gao Sun, MD
principal investigator · Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion